Research and Markets (http://www.researchandmarkets.com/research/9064f1/breast_cancer_dr)
has announced the addition of GlobalData 's new report "Breast
Cancer - Drug Pipeline Analysis and Market Forecasts to 2016" to
their offering.
“Breast
Cancer - Drug Pipeline Analysis and Market Forecasts to 2016”
Breast
Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialist, has released its latest
research, Breast
Cancer - Drug Pipeline Analysis and Market Forecasts to 2016 which
provides key data, information and analysis on the breast cancer market.
The report provides a comprehensive overview of the annualized market
data from 2001 to 2009, and forecasts forward seven years to 2016. The
research also includes market characterization, opportunities, the unmet
needs associated with breast cancer, competitive assessment, product
profiles of major marketed products and promising drugs in the pipeline,
an overview on discontinued projects, implications for future market
competition, and the key players of the breast cancer market.
The Breast Cancer Therapeutics Market is Forecast to Show High Growth
Until 2016
GlobalData's analysis suggests that the global breast cancer market was
worth $8.7 billion in 2009. It is forecast to grow at a compound annual
growth rate (CAGR) of 9.6% for the next seven years to reach $16.5
billion by 2016. The high projected growth rate is primarily
attributable to a strong pipeline. Increases in the treatment seeking
population, the diagnosis population and the availability new
first-in-class therapies with better safety and efficacy are expected to
drive the growth of the breast cancer market.
Breast Cancer Market has Strong Competition Between the Several Marketed
Combinations and Targeted Therapies
GlobalData analyzed the current competitive landscape for breast cancer
drugs and found the competition to be strong. There are more than 30
marketed products for the treatment of breast cancer, which include
chemotherapies, combinations and targeted therapies. Chemotherapy
regimens, combination therapies and targeted therapies have adverse
side-effects, sometimes fatal, despite their improved efficacy profiles.
Also, evidence of resistance to HER2-targeted trastuzumab therapy in
metastatic breast cancer patients and in early invasive phases of the
disease has raised concerns, meaning that new targeted therapies are
required. New entrants into the market will be forced to match or exceed
the efficacy and safety profiles of the currently marketed products.
A Lucrative Market with High Unmet Need
GlobalData has found that the global breast cancer market is a highly
lucrative market with high levels of unmet need. The market has several
hormonal therapies, chemotherapies, combinations and targeted therapies,
which target patients with different disease characteristics. The
efficacy profiles of these products have improved over the years,
however, the safety profiles of these drugs are still unacceptable.
Although the targeted therapies significantly improve efficacy in select
patient segments, they are costlier and also have severe adverse
effects. Therefore, the breast cancer market has high levels of unmet
need that can be fulfilled by products that target underserved patient
populations and offer improved safety and efficacy profiles.
Opportunity and Unmet Need in the Breast Cancer Market, 2010
Scope
The scope of the report includes: